Taking Action Against RSV: No Child Unprotected
Tina Q. Tan, MD
Yvonne Maldonado, MD
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
Naim Alkhouri, MD, FAASLD, DABOM
Pruritus In PN and AD: Challenge How You Manage Itch
Peter A. Lio, MD
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Luis Paz-Ares, MD, PhD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Lauren A. Byers, MD
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Joshua Richter, MD
Sagar Lonial, MD, FACP
Noopur Raje, MD
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Safety First: Navigating CELMoD-Associated Toxicities
Data Dive: Clinical Evidence Behind CELMoDs
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.